|
1）Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-88
|
|
|
|
2）Malcovati L, Germing U, Kuendgen A, et al. Time dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25: 3503-10
|
|
|
|
|
3）Kantarjian H, Obrien S, Ravandi F, et al. Proposals for a new risk model in myelodysplastic syndromes that accounts for events not considered in the original international prognostic scoring system. Cancer. 2008; 113: 1351-61
|
|
|
|
|
|
4）Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011; 29(15): 1963-70
|
|
|
|
|
|
5）Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012; 30(8): 820-9
|
|
|
|
|
|
6）Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12): 2454-65. Epub 2012 Jun 27
|
|
|
|
|
|
7）Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol. 2013; 31(21): 2671-7
|
|
|
|
|
|
8）Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nature Rev Cancer. 2012; 12: 849-59
|
|
|
|
|
|
9）Thol F, Friesen I, Damm F, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011; 29(18): 2499-506
|
|
|
|
|
|
10）Kulasekararaj AG, Smith AE, Mian SA, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013; 160(5): 660-72
|
|
|
|
|
|
11）Mishra A, Corrales-Yepez M, Ali NA, et al. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Apr 20. doi: 10.1002/ajh.23454. [Epub ahead of print] PMID: 23605934 [PubMed - as supplied by publisher]
|
|
|
|
|